Prospective, randomized, preliminary clinical trial with low-molecular-weight heparin or unfractionated heparin as periprocedural anticoagulant during elective percutaneous coronary intervention

Korean Circulation Journal

Volumn 36, Issue 8, 2006, Pages 573-577

  Her, Sung Ho ^a   Seung, Ki Bae ^a   Yoon, Hee Jeong ^a   Kim, Dong Bin ^a   Shin, Dong Il ^a   Lee, Jong Min ^a   Kim, Pum Joon ^a   Jung, Hae Ok ^a   Jin, Seung Won ^a   Chang, Ki Yuk ^a   Jeon, Doo Soo ^a   Baek, Sang Hong ^a   Hong, Soon Jo ^a   Choi, Kyu Bo ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

Anticoagulants; Enoxaparin

Indexed keywords

CREATINE KINASE MB; ENOXAPARIN; GLYCERYL TRINITRATE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TROPONIN;

ANGINA PECTORIS; ANGIOPLASTY; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 33748792047     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2006.36.8.573     Document Type: Article

References (22)

1. Narins CR, Hillegass WB Jr, Nelson CL, et al. Relation between activated clotting time during angioplasty and abrupt closure. Circulation 1996;93:667-71.
2. Popma JJ, Satler LF, Piechard AD, et al. Vascular complications after balloon and new device angioplasty. Circulation 1993;88:1569-78.
3. Antman EM, McCabe C, Gurfinkel E, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocaridal infarction: results of Thrombolysis In Myocardial Infarction (TIMI) 11B trial. Circulation 1999;100:1593-601.
4. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis. Circulation 1999;100:1602-8.
5. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-52.
6. Cohen M, Gensini GF, Maritz F, et al. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial. J Am Coll Cardiol 2003;42:1348-56.
7. Kim JH, Jeong MH, Rhew JY, et al. The long-term clinical outcomes of low molecular weight heparin combined with platelet glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndrome. Korean Circ J 2003;33:559-67.
8. Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001;103:658-63.
9. Kereiakes DJ, Grines C, Fry E, et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol 2001;13:272-8.
10. Bhatt DL, Lee BI, Casterella PJ, et al. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2003;41:20-5.
11. Chen WH, Lau CP, Lau YK, et al. Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention. J Invasive Cardiol 2002;14:439-42.
12. Choussat R, Montalescot G, Collet JP, et al. A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol 2002;40:1943-50.
13. Hwang ES, Chae IH, Park KW, et al. Clinical presentation of adverse drug reaction of dalteparin in acute coronary syndrome. Korean Circ J 2003;33:656-62.
14. Rao AK, Pratt C, Berke A, et al. Thrombolysis In Myocardial Infarction (TIMI) trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1-11.
15. Popma JJ, Ohman EM, Weitz J, Lincoff AM, Harrington RA, Berger P. Antithrombotic therapy in patients undergoing PCI. Chest 2001;119 (Suppl):321S-36S.
16. Chew DP, Bhatt DL, Lincoff AM, et al. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from six randomized, controlled trials. Circulation 2001;103:961-6.
17. Rabah MM, Premmereur J, Graham M, et al. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol 1999;84:1391-5.
18. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebo-controlled trial. Lancet 2000;356:2037-44.
19. The EPILOG Investgators. Platelet glycoprotein IIb/IIIa receptor blockede and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
20. Karsch KR, Preisack MB, Baildon R, et al. Law molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty: results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE Trial). J Am Coll Cardiol 1996;28:1437-43.
21. Montalescot G, Cohen M. Low molecular weight heparins in the cardiac catheterization laboratory. J Thromb Thrombolysis 1999;7:319-23.
22. The EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with the use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92.